

*Protective type I interferon responses in mycobacterial infection*

1 **Title**

2 Type I interferon responses contribute to immune protection against mycobacterial infection

3 **Authors**

4 Andrea Szydło-Shein<sup>1</sup>, Blanca Sanz-Magallón Duque de Estrada<sup>1</sup>, Joshua Rosenheim<sup>1</sup>, Carolin T.  
5 Turner<sup>1</sup>, Evdokia Tsaliki<sup>1</sup>, Marc C. I. Lipman<sup>2,3</sup>, Heinke Kunst<sup>4,5</sup>, Gabriele Pollara<sup>1</sup>, Philip M. Elks<sup>6</sup>,  
6 Jean-Pierre Levrard<sup>7</sup>, Elspeth M. Payne<sup>8</sup>, Mahdad Noursadeghi<sup>1</sup>, Gillian S. Tomlinson<sup>1\*</sup>

7 **Affiliations**

8 <sup>1</sup>Division of Infection and Immunity, University College London, London, UK

9 <sup>2</sup>Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK

10 <sup>3</sup>UCL Respiratory, University College London, London, UK

11 <sup>4</sup>Barts Health NHS Trust, London, UK

12 <sup>5</sup>Blizard Institute, Queen Mary University of London, London, UK

13 <sup>6</sup>The Bateson Centre, School of Medicine and Population Health, The University of Sheffield,  
14 Sheffield, UK

15 <sup>7</sup>Université Paris-Saclay, CNRS UMR9197, Institut Pasteur, Université Paris-Cité, Institut des  
16 Neurosciences Paris-Saclay, 91400 Saclay, France

17 <sup>8</sup>Research Department of Haematology, Cancer Institute, University College London, London, UK

18 \*Corresponding author

19 **Corresponding author**

20 Gillian S. Tomlinson, Email: [g.tomlinson@ucl.ac.uk](mailto:g.tomlinson@ucl.ac.uk)

21

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22 **ABSTRACT**

23 Reasons for the spectrum of severity of active tuberculosis (TB) disease are incompletely  
24 understood. We sought to identify master regulators of host immune responses that determine  
25 disease severity in pulmonary TB. We performed molecular profiling of human in vivo immune  
26 responses to discover associations with the extent of radiographic TB disease in a patient cohort.  
27 We then undertook mechanistic studies to test causality for the observed associations using the  
28 zebrafish larval *Mycobacterium marinum* infection model. Transcriptional profiling of human immune  
29 recall responses to tuberculin skin test (TST) challenge, a surrogate for immune responses to TB in  
30 the lung, revealed that type I interferon activity in the TST transcriptome was inversely associated  
31 with radiological disease severity. Abrogation of type I interferon signalling, achieved by CRISPR-  
32 mediated mutagenesis of *stat2*, led to increased susceptibility of zebrafish larvae to *M. marinum*  
33 infection, as a result of reduced recruitment of myeloid cells required to restrict mycobacterial growth,  
34 to the site of disease. Our data support a host protective role for type I interferon responses in  
35 mycobacterial infection, with potential applications for risk-stratification of adverse outcomes and  
36 development of a host-directed therapy to mitigate against severe disease.

37 **ONE SENTENCE SUMMARY**

38 Type I interferon responses contribute to host immune protection in mycobacterial infection by  
39 recruitment of myeloid cells to the site of disease.

40

## 41 INTRODUCTION

42 *Mycobacterium tuberculosis* (Mtb) infection results in diverse clinical manifestations, ranging from  
43 asymptomatic infection to active tuberculosis (TB), which comprises an enormous spectrum of  
44 disease severity (1, 2). Although we know that immune responses contribute to the risk of disease,  
45 current understanding of the role of immune response variation in disease severity is limited.  
46 Identification of immune correlates of disease severity may offer new insights into the immune  
47 pathways that contribute to protection and pathogenesis. This is necessary to enable novel vaccine  
48 design and evaluation, stratify disease risk in people who become infected and inform development  
49 of novel host-directed therapies to shorten treatment regimens, mitigate against antimicrobial  
50 resistance, and against the chronic sequelae of tissue injury in TB (3).

51 Variation in tissue immunology of human TB at the site of established disease is likely confounded  
52 by differences in the chronicity of the disease process. To overcome this limitation, we evaluated  
53 in vivo immune responses at the site of a standardised antigenic challenge using the tuberculin skin  
54 test (TST). We have previously shown that transcriptional profiling of skin biopsies from the site of  
55 the TST provides comprehensive molecular and systems level evaluation of human in vivo immune  
56 responses to Mtb with significantly greater sensitivity than conventional clinical and histological  
57 assessments (4, 5). The TST gene signature is enriched within pulmonary TB granulomas and  
58 accounts for genome-wide differences in the transcriptomes of TB infected lung compared to healthy  
59 lung tissue (5, 6). Therefore, the TST provides a faithful and readily accessible surrogate to study  
60 immune responses at the site of TB disease.

61 In the present study, we identified quantitative variation in immune pathways in the TST response  
62 correlated with the severity of human TB disease, and then tested the hypothesis that these  
63 pathways were causally related to outcomes of *Mycobacterium marinum* infection in zebrafish larvae.  
64 This natural host-pathogen interaction generates granulomatous inflammation that recapitulates key  
65 aspects of human TB pathology and in particular, provides unparalleled opportunities to study innate  
66 immune responses in isolation, given the absence of functional adaptive immunity until 3-4 weeks  
67 (7). Our innovative strategy revealed an inverse relationship between type I interferon activity and  
68 radiographic severity of human TB, suggesting a host-protective role for type I interferons, that we  
69 confirmed in zebrafish larvae by showing that mutagenesis of *stat2* to model abrogation of  
70 downstream type I interferon signalling led to increased severity of *M. marinum* infection.

## 71 RESULTS

### 72 **Outlier analysis of the TST transcriptome defines human in vivo immune responses to** 73 **active tuberculosis**

74 We supplemented data from our previously reported TST transcriptional responses (8) to provide a  
75 total sample size of 51 people with microbiologically confirmed pulmonary TB who were within one  
76 month of commencing anti-tuberculous chemotherapy (Table 1, Fig. S1A, B). We evaluated disease  
77 severity using a published radiographic scoring system which incorporates extent of disease and the  
78 presence of cavitation on chest x-ray (9). In order to capture the inter-individual variation in immune  
79 response to the mycobacterial challenge, outlier profile analysis (10) was used to identify transcripts  
80 in the TST of each individual that were significantly enriched compared to gene expression in control  
81 data from skin biopsies at the site of saline injections. The integrated list of outlier genes statistically  
82 enriched in TST samples compared to control saline samples from all 51 individuals defined an active  
83 TB TST transcriptome comprised of 3222 transcripts. This analysis revealed that although some  
84 aspects of the TST response are consistent in all people, there is also considerable variability  
85 between individuals (Fig. S1C). The 3222 transcripts identified by this approach, were enriched for  
86 canonical pathways involved in cell mediated responses, consistent with our previous description of  
87 the TST gene signature identified by conventional differential gene expression analysis (5, 8) (Fig.  
88 S1D).

### 89 **Reduced type I interferon activity in the TST transcriptome is associated with increased** 90 **severity of human TB disease**

91 Next, we sought to identify immunological pathways correlated with disease severity. We identified  
92 individual genes in the TST transcriptome that showed statistically significant correlations with the

### Protective type I interferon responses in mycobacterial infection

93 radiographic severity score. We subjected these genes to Ingenuity Pathway Analysis upstream  
94 regulator analysis to collate groups of co-regulated genes (Fig. 1A and Fig. S2A). These were  
95 annotated by their upstream regulators at the level of cytokines, transmembrane receptors, kinases  
96 and transcriptional regulators, representing the key components of signalling pathways which  
97 mediate immune responses. To provide increased confidence that these modules represented co-  
98 regulated genes in each molecular pathway, we retained only those that had significantly greater co-  
99 correlated expression than modules of genes randomly selected from our TST transcriptomes (11).  
100 111 modules were identified among genes inversely correlated with radiographic TB severity,  
101 suggesting they may contribute to host protection against severe disease (Fig. 1A-C and Fig. S2B).  
102 These included transcriptional modules representing pro-inflammatory cytokine activity (tumour  
103 necrosis factor alpha and interleukin (IL)1 beta), interferon gamma and T cell activity, consistent with  
104 existing evidence predominantly supporting their protective roles in TB (12) (Fig. 1B). In addition, we  
105 found enrichment of multiple co-regulated gene networks attributed to type I interferon signalling,  
106 suggesting that type I interferon responses may also contribute to host protection in mycobacterial  
107 infection (Fig. 1B, C). Interferon gamma was also predicted to regulate one of only two small putative  
108 networks within genes positively correlated with disease severity; the other driven by TCL1A, an AKT  
109 kinase activator that promotes cellular survival (13) (Fig. S2C).

110 To validate the immunological responses predicted to be associated with disease severity by  
111 upstream regulator analysis, we quantified the expression of two independently derived and largely  
112 non-overlapping type I interferon inducible gene modules reflecting the biological activity of type I  
113 interferons (Table S1) (5, 8), within the TB TST transcriptome (Fig. 1D). This provided independent  
114 validation of the inverse relationship between type I interferon responses and radiographic severity  
115 of TB (Fig. 1E), suggestive of a host-protective role. By contrast, the expression of the entire TST  
116 transcriptome and that of three distinct independently derived interferon gamma inducible gene  
117 modules (5) (Table S1) did not correlate with disease severity (Fig. S3).

### 118 **stat2 CRISPR zebrafish larvae exhibit increased susceptibility to *M. marinum* infection**

119 The TST transcriptome does not solely reflect anti-mycobacterial T cell memory (4) and type I  
120 interferons are primarily induced following activation of innate immune recognition pathways (14).  
121 Therefore, to evaluate whether impaired type I interferon responses cause more severe  
122 mycobacterial disease, we exploited the zebrafish larval *M. marinum* infection model, which allows  
123 exclusive assessment of innate immunity (7). The mammalian canonical type I interferon signalling  
124 pathway is highly conserved in zebrafish (15, 16) (Fig. 2A). First, we confirmed that intravenous  
125 *M. marinum* infection of wild type zebrafish larvae induces a type I interferon response, as evidenced  
126 by enrichment for two distinct independently derived transcriptional modules reflecting type I  
127 interferon activity (11, 16) (Table S1) within genome-wide transcriptomic data obtained after four  
128 days of mycobacterial growth (Fig. 2B, C). To block downstream type I interferon signalling we used  
129 CRISPR-mediated mutagenesis of *stat2*, a subunit of the interferon stimulated gene factor (ISGF)3,  
130 the principal transcription factor complex which induces expression of type I interferon stimulated  
131 genes (ISG) (17–19), for which there is a single zebrafish orthologue (15) (Fig. 2A). Injection of three  
132 guide RNA/Cas9 ribonucleoprotein (RNP) complexes each targeting a distinct *stat2* exon, into one  
133 cell stage wild type zebrafish embryos led to >90% efficient mutagenesis, confirmed by next-  
134 generation sequencing (Fig. S4A and Fig. S5A). We verified loss of functional downstream type I  
135 interferon signalling by showing that induction of the classical ISG Mxa (16, 19) by recombinant  
136 interferon phi 1, measured by expression of a reporter *mxmCherry* transgene, was significantly  
137 attenuated in *stat2* CRISPRs compared to siblings injected with “scrambled” (negative control)  
138 RNPs designed to lack genomic targets (Fig. S4B and Fig. S5B-C). *stat2* CRISPRs developed  
139 normally up to five days post-fertilisation (Fig. S5B).

140 There was no difference in survival of *M. marinum* infected *stat2* CRISPRs and scrambled RNP  
141 injected siblings (Fig. 3A, B) within the timeframe of our experiments. However, mycobacterial  
142 burden, the number of bacterial foci and the spatial dissemination of bacteria, determined by  
143 quantitation of fluorescent foci of *M. marinum*, were all significantly higher in intravenously infected  
144 *stat2* CRISPRs compared to control RNP injected siblings, indicative of more severe disease (Fig.  
145 3A, C-E). These findings are consistent with a host protective role for type I interferons in  
146 mycobacterial infection, as suggested by our observation of an association between reduced type I  
147 interferon activity and increased disease severity in human TB (Fig. 1).

## 148 **Steady state neutrophil numbers are reduced in *stat2* CRISPR zebrafish larvae**

149 Macrophages are critically important for control of *M. marinum* infection in zebrafish larvae (20–22)  
150 and neutrophils may also contribute to mycobacterial killing (23, 24). Therefore, to investigate the  
151 mechanisms by which *stat2* deficiency leads to worse mycobacterial infection we used transgenic  
152 zebrafish lines with fluorescent immune cell lineages to generate *stat2* CRISPRs that have  
153 fluorescent macrophages or neutrophils. First, we asked whether *stat2* disruption impacted steady  
154 state macrophage or neutrophil numbers. We demonstrated by quantitative fluorescence  
155 microscopy, using integrated fluorescence as a surrogate for cell number, that *stat2* deficiency did  
156 not affect baseline macrophage numbers (Fig. 4A, B). However, it was associated with reduced  
157 neutrophil numbers (Fig. 4C, D).

## 158 **Recruitment of macrophages but not neutrophils to the site of sterile injury is *stat2*** 159 **dependent**

160 Type I interferons have previously been shown to influence cellular migration (14, 25). Therefore,  
161 we tested macrophage and neutrophil recruitment in *stat2* CRISPRs using a tailfin transection  
162 model of sterile injury, most commonly used to evaluate neutrophil recruitment (26) (Fig. S4C). The  
163 timing of neutrophil homing to the site of sterile tail fin transection was normal in *stat2* CRISPRs,  
164 with maximal accumulation at six hours and dissipation of recruited cells becoming evident by 24  
165 hours, similar to that of control RNP injected embryos (Fig. 5A, B) and in keeping with previous  
166 studies (26, 27). Despite baseline neutropenia, the number of neutrophils at the wound site at the  
167 point of maximal recruitment in *stat2* CRISPRs exceeded that of control RNP injected embryos.  
168 But by 24 hours the number of neutrophils at the injury site was significantly reduced in *stat2*  
169 CRISPRs, likely reflecting the attenuated increase in total neutrophil numbers in response to the  
170 acute inflammatory challenge (Fig. 5C, D).

171 As previously reported, macrophage recruitment to the tail wound site was slower than that of  
172 neutrophils (27, 28). Very few macrophages were present at the tailfin transection site by one hour  
173 in either *stat2* disrupted or control transgenic larvae, but recruitment progressively increased until 24  
174 hours in both groups (Fig. 6). Fewer macrophages were found in the vicinity of the wound site at all  
175 time points post-injury in *stat2* CRISPR transgenic embryos compared to control RNP injected  
176 siblings, the majority being located outwith the tailfin (Fig. 6). Taken together these data suggest that  
177 *stat2* is necessary for macrophage recruitment but non-essential for neutrophil recruitment to a  
178 sterile injury site. In addition, baseline neutropenia did not impact the number of cells localised to the  
179 wound at peak neutrophil recruitment.

## 180 **Recruitment of myeloid cells to the site of *M. marinum* infection is *stat2* dependent**

181 Next we focused on macrophage recruitment to the site of mycobacterial infection because this has  
182 been reported to be crucial for control of *M. marinum* growth in zebrafish larvae (21). We found a  
183 significant reduction in the number of macrophages recruited to the site of localised hindbrain  
184 *M. marinum* infection in *stat2* deficient transgenic zebrafish larvae compared to their counterparts  
185 injected with scrambled RNPs (Fig. S4D and Fig. 7A, B). We then evaluated whether *stat2* disruption  
186 affected recruitment of neutrophils to the site of mycobacterial infection. We found that in contrast to  
187 their normal peak recruitment to a sterile wound, the number of neutrophils attracted to the site of  
188 mycobacterial disease was also significantly diminished in *stat2* CRISPRs (Fig 7C, D). Collectively,  
189 these results demonstrate that myeloid cell recruitment to the site of *M. marinum* infection is *stat2*  
190 dependent.

191 In total, the recruitment studies suggest that *stat2* disruption leads to a broad defect in macrophage  
192 recruitment to both infectious and non-infectious inflammatory foci. By contrast, *stat2* is non-essential  
193 for neutrophil migration to sterile injury. The latter finding is consistent with defective migration, rather  
194 than neutropenia, being the principal mechanism for reduced neutrophil numbers at the site of  
195 *M. marinum* infection.

## 196 **DISCUSSION**

197 We have taken an innovative approach, combining molecular and systems level evaluation of human  
198 immune responses to a standardised experimental challenge, to identify master regulators of



*Protective type I interferon responses in mycobacterial infection*

199 biological pathways associated with TB disease severity. We experimentally validated host factors  
200 responsible for differences in phenotype using a relevant, tractable animal model which represents  
201 a natural host-pathogen pairing (7). Molecular interrogation of human in vivo responses to Mtb  
202 revealed that reduced type I interferon activity within the TST transcriptome was associated with  
203 worse pulmonary disease. Deficient type I interferon signalling, achieved by genetic disruption of  
204 *stat2*, led to more severe mycobacterial infection in zebrafish larvae, via a mechanism involving  
205 impaired recruitment of macrophages and neutrophils to the site of disease and reduced neutrophil  
206 numbers at baseline. Taken together our results demonstrate an important role for type I interferon  
207 responses in contributing to innate immune protection against mycobacterial disease.

208 Peripheral blood interferon-inducible gene expression that diminishes with successful treatment is  
209 detectable in human active TB (29–31). These transcriptional signatures comprise both type I and  
210 type II interferon inducible genes but have mainly been interpreted as type I interferon responses,  
211 fostering the view that type I interferons are detrimental to the host in human TB. Mouse data  
212 predominantly suggest that type I interferon responses contribute to increased susceptibility to  
213 mycobacterial infection by mechanisms including antagonism of IL1 mediated protection (32–34)  
214 and reduced responsiveness of macrophages to interferon gamma (35). However, this phenotype  
215 has not been universally observed, likely due to differences in host and pathogen genetics (36).  
216 Moreover, impaired type I interferon responses are generally associated with relatively minor  
217 differences in bacterial burden or survival (36). Of note, Mtb is not a natural mouse pathogen, and  
218 this approach may not model host-pathogen interactions in human TB faithfully (37).

219 In support of a protective role for type I interferons, adjunctive interferon alpha therapy in addition to  
220 conventional anti-tuberculous antibiotic treatment led to symptomatic and radiological improvement,  
221 with a reduction in bacterial burden in respiratory tract samples, in small-scale human studies (38–  
222 40). In keeping with this, an early peripheral blood type I interferon-inducible gene signature predicts  
223 successful BCG-induced protection of macaques from subsequent Mtb challenge (41). Type I  
224 interferon mediated restriction of mycobacterial growth in in vitro granulomas comprising collagen  
225 impregnated microspheres containing Mtb infected human peripheral blood mononuclear cells  
226 (PBMC) (42) also suggests that type I interferon responses benefit the host.

227 Our observation of reduced recruitment of macrophages to the site of disease is likely the most  
228 important factor driving increased susceptibility to *M. marinum* infection in *stat2* CRISPRants.  
229 Although macrophages have been implicated in the dissemination of *M. marinum* in zebrafish larvae  
230 (20, 43), reduction of total macrophage numbers, impaired macrophage migration to the site of  
231 mycobacterial infection or failure to control intracellular bacterial growth within macrophages have  
232 all been associated with poor outcome (20–22, 44, 45). In contrast, increasing macrophage numbers  
233 via augmentation of M-CSF signalling either pre- or post-granuloma formation, promotes resistance  
234 to *M. marinum* infection by reducing granuloma necrosis, with consequent curtailment of  
235 extracellular mycobacterial growth (21). The recent report that human genetically inherited CCR2  
236 deficiency is associated with reduced pulmonary recruitment of monocytes, resulting in depleted  
237 numbers of functionally normal alveolar macrophages and increased susceptibility to mycobacteria,  
238 is also consistent with the notion that adequate numbers of macrophages are important for protective  
239 anti-mycobacterial immunity (46).

240 The reduction in neutrophils present at the site of *M. marinum* infection in *stat2* CRISPRants may have  
241 arisen due to baseline neutropenia, defective migration or both combined. On the basis that steady  
242 state neutropenia did not affect the timing and magnitude of peak neutrophil recruitment to sterile  
243 injury, impaired migration is probably the main driver of this phenotype, which likely also contributed  
244 to increased severity of mycobacterial disease. Previous data show that reduced access of  
245 neutrophils to mycobacteria leads to increased bacterial burden in a zebrafish line in which  
246 neutrophils express mutant *cxc4*, resulting in peripheral neutropenia and impaired neutrophil  
247 recruitment to sites of inflammation, due to their retention in haematopoietic tissue (23, 47).

248 Our study has some limitations. We were not able to address the reasons for variation in type I  
249 interferon activity in our human cohort. Serum samples for measurement of autoantibodies to type I  
250 interferons are not available and our sample size is insufficient for robust detection of associations  
251 between genetic variation and the expression levels of type I interferon signalling pathway genes.  
252 We were also unable to completely disentangle whether reduced neutrophil recruitment to the site  
253 of *M. marinum* infection was a consequence of neutropenia or impaired migration. We have not

254 determined the mechanism by which attenuated type I interferon signalling leads to reduced myeloid  
255 cell recruitment to *M. marinum*. The expression of several chemokines is type I interferon inducible  
256 (25, 48, 49) and the CCR2-CCL2 and CXCR3-CXCL11 chemokine axes are known to be involved  
257 in macrophage recruitment to *M. marinum* (43, 50). Future studies are required to test the hypothesis  
258 that *stat2* mutagenesis disrupts chemokine-mediated cellular recruitment to the site of mycobacterial  
259 disease. Nonetheless, our work provides new insights into type I interferon mediated host protection  
260 against mycobacterial infection.

261 Variation in type I interferon responses may arise due to genetically or epigenetically encoded  
262 variation in the immune response to Mtb, neutralising type I interferon auto-antibodies, burden and  
263 virulence of the mycobacterial inoculum and stochasticity in the immune response pathway following  
264 exposure (51–55). A central tenet of all these possibilities is that differences in the host immune  
265 response to Mtb lead to differences in disease severity. Our findings have potential implications for  
266 risk stratification of individuals in whom any of these mechanisms predisposing to low type I  
267 interferon activity are identified. In active TB, such individuals could be targeted for longer or more  
268 intensive drug regimens, or adjunctive type I interferon therapy delivered to the respiratory tract, to  
269 mitigate against severe disease. Early intervention with type I interferon treatment, before destruction  
270 of the lung parenchyma, is likely to be crucial to augment macrophage containment of Mtb, but timing  
271 and duration of therapy will require evaluation in relatively large-scale experimental medicine trials.

## 272 **MATERIALS AND METHODS**

### 273 **Ethics statement**

274 The study was approved by the London Bloomsbury Research Ethics Committee (16/LO/0776).  
275 Written informed consent was obtained from all participants.

### 276 **Study design**

277 We aimed to identify master regulators of human immune responses that correlate with severity of  
278 TB disease, using transcriptional profiling of biopsies from the TST as a surrogate for immune  
279 responses to TB in the lung and to test causation for observed associations by genetic manipulation  
280 of identified upstream regulator molecules in the zebrafish larval mycobacterial infection model. To  
281 encompass a broad spectrum of disease severity we recruited 51 adults (>18 years) from four  
282 London hospitals, newly diagnosed with smear or culture positive pulmonary TB, who were within  
283 four weeks of starting treatment. This is in keeping with the median sample size of previous studies  
284 which have successfully demonstrated a relationship between severity of TB disease and  
285 immunological parameters (29, 56–59). Individuals with coincident human immunodeficiency virus  
286 infection, malignancy, taking immunomodulatory therapy, a history of immunization within the  
287 preceding two weeks or previous keloid formation, or unable to give informed consent were  
288 excluded. Study participants underwent intradermal injection of 0.1 ml of two units of tuberculin (AJ  
289 Vaccines) or saline in the volar aspect of the forearm as previously described (4, 5, 8). At 48 hours  
290 clinical induration at the injection site was measured, immediately prior to sampling by 3mm punch  
291 biopsy as previously described (4, 5). Additional saline samples from individuals with cured or latent  
292 TB, BCG vaccine recipients and healthy volunteers have been described previously (8).

### 293 **RNA purification from skin biopsy and zebrafish embryo samples**

294 Skin biopsies were homogenized as previously described (8). Pooled zebrafish embryos (25-30 per  
295 experimental condition) collected in Qiazol (Qiagen) were homogenized in CK14 lysing kit tubes  
296 (Bertin Instruments) using a Precellys Evolution homogenizer (Bertin Instruments) for 10-20 seconds  
297 at 5500 rpm. Total RNA from skin biopsies and zebrafish samples was purified using the RNEasy  
298 mini and micro kits (Qiagen), respectively, according to the manufacturer's instructions. Genomic  
299 DNA was removed using the TURBO DNA-free kit (ThermoFisher).

### 300 **Transcriptional profiling of skin biopsy and zebrafish larval samples**

301 Genome-wide mRNA sequencing was performed as previously described (8, 60). Complementary  
302 DNA (cDNA) libraries were prepared using the KAPA HyperPrep kit (Roche). Sequencing was  
303 performed in paired-end mode with the NextSeq 500 High Output 75 Cycle Kit (Illumina) using the  
304 NextSeq500 system (Illumina) according to the manufacturer's instructions, generating a median of  
305 22 million (range 12.3-27.9 million) 41 base pair reads per human sample and 16.8 million (range

306 15.1-18.1 million) reads per zebrafish sample. Transcript alignment and quantitation against the  
307 Ensembl GRCh38 human genome assembly release 100 or GRCz11 zebrafish genome assembly  
308 release 104 was performed using Kallisto (61). Transcript-level output counts and transcripts per  
309 million (TPM) values were summed on gene level and annotated with Ensembl gene ID, gene name,  
310 and gene biotype using the R/Bioconductor packages tximport and BiomaRt (62, 63). Downstream  
311 analysis was performed using R 3.6.3 on log<sub>2</sub> transformed TPM values for protein-coding genes  
312 only. TPM values <0.001 were set to 0.001 prior to log<sub>2</sub> transformation. To determine the need for  
313 and effect of batch correction in the human data, principal component analysis (PCA) was performed  
314 using the prcomp R function on the integrated list of 6802 genes with the 10% lowest variance in  
315 expression for each library preparation date. This revealed separation of three samples in PC1, likely  
316 accounted for by lower RNA concentrations or RIN values compared to the rest of the dataset (Fig.  
317 S1A). After batch correction performed using the ComBat function of the sva R package (64),  
318 allocating samples with PC1 score <0 and >0 to separate batches, this was no longer evident (Fig.  
319 S1B).

### 320 **Radiographic quantitation of TB severity**

321 Disease severity was evaluated by estimating the extent of radiographic abnormalities and whether  
322 cavitation was present on chest x-ray at the time of diagnosis, as previously described (8, 9).

### 323 **Outlier analysis**

324 The BioBase Bioconductor R package was used to perform outlier analysis based on the z-score  
325 outlier detection (ZODET) algorithm (10), to identify transcripts in each TST sample whose  
326 expression was significantly higher than the mean expression in control saline samples (>2SD,  
327 p value <0.05), with a fold difference filter of >1 log<sub>2</sub>. Chi-squared tests implemented in R were then  
328 used to identify outlier genes statistically enriched in TST samples compared to saline samples,  
329 using a p value <0.05. To avoid type 2 error no correction for multiple testing was used in this  
330 analysis. In instances where multiple Ensembl gene IDs were associated with a single gene symbol,  
331 duplicate gene symbols were removed to retain the replicate with the highest expression for each  
332 sample.

### 333 **Pathway enrichment analysis**

334 The biological pathways represented by the TST transcriptome were identified by Reactome  
335 pathway enrichment analysis using XGR as previously described (65, 66). For visualization, 15  
336 pathway groups were identified by hierarchical clustering of Jaccard indices to quantify similarity  
337 between the gene compositions of each pathway. For each group the pathway term with the largest  
338 number of annotated genes was then selected as representative of enriched biology.

### 339 **Upstream regulator analysis**

340 TST transcriptome genes whose expression was significantly correlated with radiographic severity  
341 of TB disease were identified by Spearman rank correlation, p value <0.05, without correction for  
342 multiple testing, to prevent type 2 error. Genes positively and negatively correlated with disease  
343 severity were separately subjected to Ingenuity Pathway Analysis (Qiagen) to identify upstream  
344 molecules responsible for their transcriptional regulation. This analysis was restricted to molecules  
345 annotated with the following functions: cytokine, transmembrane receptor, kinase and transcriptional  
346 regulator, representing the canonical components of pathways which mediate transcriptional  
347 reprogramming in immune responses. Enriched molecules with an adjusted p value <0.05 were  
348 considered statistically significant.

### 349 **Upstream regulator functional modules**

350 TST gene modules representing the functional activity of their upstream molecule were identified as  
351 previously described (11). In brief, we calculated the average correlation coefficient for pairwise  
352 correlations of the expression levels of the target genes associated with each predicted upstream  
353 regulator. We compared these to the distribution of average correlation coefficients obtained from  
354 100 iterations of randomly selecting equivalent sized groups of genes from the TST transcriptome.  
355 Only target gene modules with average correlation coefficients higher than the mean of the  
356 distribution of equivalent sized randomly selected groups by  $\geq 2$  SD (Z score  $\geq 2$ ) with false discovery  
357 rate <0.05, were retained. We visualised these upstream regulator modules as network diagrams



358 using the Force Atlas two algorithm in Gephi v0.9.2 (67), depicting all statistically over-represented  
359 molecules (false discovery rate <0.05) predicted to be upstream of  $\geq 4$  target genes.

### 360 **Transcriptional modules**

361 Interferon inducible transcriptional module gene lists are provided in Table S1. Independently derived  
362 human type I and type II interferon inducible gene modules were described previously (5, 8, 11).  
363 Two further modules were derived to distinguish type I or type II interferon inducible gene expression  
364 using published transcriptional data for primary human keratinocytes stimulated with a selection of  
365 cytokines (Gene Expression Omnibus accession: GSE36287) (68). Stimulus-specific modules for  
366 type I interferon (interferon alpha) and type II interferon (interferon gamma) were derived by selecting  
367 genes overexpressed >4-fold in the cognate cytokine condition relative to all non-cognate conditions  
368 combined (paired t test with  $\alpha$  of  $p < 0.05$  without multiple testing correction), excluding genes also  
369 induced by each non-cognate cytokine condition, using the same criteria. The babelgene R package  
370 (<https://igordot.github.io/babelgene/>) was used to convert human gene symbols to their respective  
371 zebrafish orthologues to generate the zebrafish Stat1 module, excluding zebrafish genes reported  
372 to be an orthologue of more than one human gene. The zebrafish type I interferon inducible gene  
373 module comprises 360 genes whose expression was significantly induced ( $\geq 2$  fold, adjusted p value  
374 <0.05) six hours after intravenous injection of three day post-fertilisation (dpf) larvae with 1 nl of  
375 recombinant interferon phi 1 protein (1 mg/ml) as previously described (16).

### 376 **Venn diagrams**

377 Area-proportional Venn diagrams visualizing the overlap between constituent genes in  
378 transcriptional modules were generated using BioVenn (69).

### 379 **Zebrafish husbandry**

380 Zebrafish were raised and maintained at 28.5°C following a 14/10 light/dark cycle according to  
381 standard protocols (70) in University College London (UCL) and Neuro-PSI Zebrafish Facilities. All  
382 work was approved by the British Home Office (Project License PP8780756) and the French Ministry  
383 for Research and Higher Education (Project Licence 39238). All experiments were performed in  
384 accordance with the relevant guidelines and regulations, on larvae up to five days post-fertilisation,  
385 before they are protected under the Animals (Scientific Procedures) Act. Adult zebrafish were  
386 spawned to collect embryos for experiments. Table S2 lists the lines used in this study (26, 71, 72).  
387 Embryos were maintained at 28.5°C in egg water containing 60  $\mu\text{g/ml}$  Tropic Marin Sea Salt  
388 (Norwood Aquarium) and anaesthetised with egg water containing 200  $\mu\text{g/ml}$  buffered tricaine (3-  
389 aminobenzoic acid ethyl ester) (Sigma-Aldrich) during injection, tail fin transection and imaging.  
390 Larvae used for in vivo imaging were maintained in egg water supplemented at 24 hours post-  
391 fertilisation (hpf) with 0.003% PTU (1-phenyl-2-thiourea) (Sigma-Aldrich) to inhibit melanisation.

### 392 **CRISPR Generation**

393 To maximise the likelihood of loss of functional protein we employed a previously described triple-  
394 exon targeting approach (73), with the modification that Cas9 protein was not diluted before use.  
395 CRISPR RNA (crRNA) (Alt-R CRISPR-Cas9 crRNA), tracrRNA (Alt-R CRISPR-Cas9 tracrRNA) and  
396 recombinant Cas9 protein (Alt-R Streptococcus pyogenes Cas9 Nuclease V3) were obtained from  
397 Integrated DNA Technologies (IDT). Three pre-designed crRNAs targeting distinct exons were  
398 selected for the *stat2* gene, prioritizing those that targeted early, asymmetric (not divisible by three)  
399 exons common to both protein-coding transcripts, with low off-target and high on-target scores and  
400 in a genomic position which allowed design of primers flanking the target site to generate a ~200 bp  
401 amplicon, for verification of mutagenesis by next generation sequencing (MiSeq). crRNA sequences  
402 and genomic locations are provided in Table S3. To generate gRNAs equal volumes of crRNA and  
403 tracrRNA diluted to 61  $\mu\text{M}$  in Duplex buffer (IDT) were annealed at 95°C for 5 minutes. Equal  
404 volumes of gRNA (61  $\mu\text{M}$ ) and Cas9 protein (61  $\mu\text{M}$ ) were incubated at 37°C for 5 minutes to  
405 assemble separate 30.5  $\mu\text{M}$  ribonucleoproteins (RNPs) for each target. Equal volumes of the three  
406 RNPs were pooled, prior to injection giving a final concentration of 10.2  $\mu\text{M}$  for each. Negative control  
407 “scrambled” crRNAs computationally designed to be non-targeting (Alt-R CRISPR-Cas9 Negative  
408 Control crRNA #1, #2, #3) were prepared and pooled as described above. 0.5 nl of pooled *stat2*  
409 RNPs or scrambled RNPs was injected into the yolk sac of single-cell stage wild type or transgenic  
410 zebrafish embryos before cell inflation as previously described (73). After injections embryos were

411 transferred into sterile petri dishes with fresh egg water and maintained at 28.5°C to the appropriate  
412 age for experiments, as described below.

### 413 Interferon phi 1 stimulation

414 Three dpf *stat2* CRISPRant *Tg(mxa:mCherry)* larvae and scrambled RNP injected siblings were  
415 injected in the coelomic cavity with 1 nl of recombinant zebrafish interferon phi 1 protein (1.25 mg/ml),  
416 produced as previously described (74). *stat2* and control CRISPRants were shuffled so that injections  
417 were performed blindly. Bovine serum albumin (BSA) (1.25 mg/ml) was injected as a control.  
418 Interferon phi 1 and BSA solutions were supplemented with 0.2% phenol red (Sigma-Aldrich) to  
419 visualize the inoculum. Induction of Mxa reporter expression was determined by fluorescence  
420 microscopy 24 hours post-injection.

### 421 *M. marinum* infection

422 *M. marinum* M strain expressing the pmsp12 mWasabi (75) or psMT3 mCherry plasmid (76) was  
423 cultured using Middlebrook 7H10 agar (Becton Dickinson and Company) supplemented with 0.5%  
424 oleic acid/albumin/dextrose/catalase (OADC) (Becton Dickinson and Company), 0.5% glycerol  
425 (Sigma-Aldrich) and hygromycin (50 µg/ml) (Fisher Scientific). To generate bacterial suspensions for  
426 injection, *M. marinum* from agar plates was cultured statically at 28.5°C for 24-36 hours in 10 ml  
427 Middlebrook 7H9 broth (Becton Dickinson and Company) supplemented with 10%  
428 albumin/dextrose/catalase (ADC) (Becton Dickinson and Company) and hygromycin (50 µg/ml)  
429 (Fisher Scientific). Bacteria were harvested at mid-log growth (optical density (OD)<sub>600nm</sub> 0.7–1),  
430 (OD)<sub>600nm</sub> 1 representing 10<sup>8</sup> colony forming units (cfu)/ml, washed three times in phosphate  
431 buffered saline (PBS) (Gibco) and resuspended in 2% polyvinylpyrrolidone (PVP)40 (Sigma-  
432 Aldrich)/PBS containing 10% phenol red (Sigma-Aldrich) to aid visualisation of injections (77).

433 Zebrafish embryos were manually dechorionated using jeweller's forceps (Dumont #5, World  
434 Precision Instruments) prior to bacterial infection. To generate systemic infection, 400 cfu  
435 *M. marinum* in a volume of 1 nl were microinjected into the caudal vein of embryos staged at  
436 28-30 hpf. Four days post-infection, embryos were either subjected to fluorescence microscopy to  
437 measure disease severity or 25-30 per condition pooled and harvested in Qiazol (Qiagen) for  
438 evaluation of immune responses by RNAseq. To generate localised infection, 200 cfu *M. marinum*  
439 in a volume of 1 nl were injected into the hindbrain ventricle (HBV) of two dpf zebrafish larvae.  
440 Cellular recruitment was evaluated by fluorescence microscopy at 6-18 hours post-infection.

### 441 Tailfin transection

442 Tailfin transections were performed as described previously (26, 78). Briefly, live anaesthetised three  
443 dpf zebrafish larvae were transferred with a 1 ml Pasteur pipette (Scientific Laboratory Supplies) to  
444 a sterile petri dish containing 2% agarose (Bioline). Transections of the caudal fin were performed  
445 using a sterile microscalpel (World Precision Instruments) by applying steady downward pressure to  
446 create the incision at the boundary with the notochord. Following injury, larvae were rinsed in egg  
447 water, and maintained in individual wells of a 96-well tissue culture plate (TPP) at 28.5°C until live  
448 imaging to quantify neutrophil or macrophage recruitment to the site of injury at 1, 6 and 24 hours-  
449 post-wound (hpw).

### 450 Fluorescence microscopy

451 All fluorescence microscopy was performed on live, anaesthetised larvae. For quantitation of bacterial  
452 burden and dissemination four days post-infection, steady state neutrophil numbers at two dpf and  
453 cellular recruitment at 2-4 dpf, larvae were imaged using an M205FA stereofluorescence microscope  
454 (Leica) with a 1x objective. Larvae were imaged on a flat 1% agarose plate for quantitation of severity  
455 of mycobacterial infection and steady state neutrophil numbers and a 96-well tissue culture plate  
456 (TPP) in which the wells were coated with 1% agarose, for cellular recruitment to tailfin transection.  
457 Micro-wells were created in 1% agarose using a Stampwell Larvae 1 device (Idylle) for optimal  
458 positioning of 2-3 dpf larvae for imaging of cellular recruitment to hindbrain ventricle *M. marinum*  
459 infection. Brightfield and fluorescence images were captured using a DFC365 FX camera (Leica)  
460 and exported as 16-bit Tagged Image Format (TIF) files for analysis. For quantitation of steady state  
461 macrophage numbers three dpf larvae were imaged in 96-well alignment plates (Funakoshi)  
462 containing 75 µl egg water per well using a high-content wide-field fluorescence microscope  
463 (Hermes, IDEA Bio-Medical) with a 4x objective, capturing five z planes 50.6 µm apart in four

464 contiguous fields of view per embryo. We created an ImageJ macro to semi-automate generation of  
465 single maximum intensity projection z-stack montages from the Hermes images, which were saved  
466 as 16-bit TIF files for analysis (Table S4. Mxa reporter expression was recorded with an EVOS  
467 M7000 microscope (ThermoFisher) equipped with a 2x/NA0.06 objective and Texas Red  
468 fluorescence cube. Larvae were positioned laterally in micro-wells created in 2% agarose with an in-  
469 house-printed stamp. A single fluorescence plane was recorded as the depth of field is sufficient to  
470 capture the entire larva. Transmitted light images were also recorded and both were exported as 16-  
471 bit TIF files.

## 472 **Image analysis**

473 To quantify bacterial burden, number of bacterial foci and spatial distribution of bacteria, images  
474 were analysed using custom QuantiFish software, previously developed in our group, to enable rapid  
475 quantitation of fluorescent foci in zebrafish larvae (79). Mxa reporter fluorescence was measured  
476 with ImageJ. Transmitted and fluorescence images were stacked. Images were slightly rotated to  
477 horizontality where necessary. A 600x100 pixel rectangular region of interest was defined on the  
478 transmitted light image to encompass the entire gut and liver areas. Mean fluorescence intensity was  
479 then measured on the fluorescence image. For quantitation of total cell number and recruitment of  
480 fluorescent immune cells to the site of tailfin transection we developed a new custom Python script  
481 which enables quantitation of integrated fluorescence within concentric zones (known as Sholl  
482 circles) (80). To achieve this, the script leverages the OpenCV, NumPy (81), Matplotlib, SciPy  
483 (<http://www.scipy.org>), scikit-image (82) and pandas Python libraries to facilitate image processing  
484 and data extraction (Table S5. First the user is prompted to select a folder containing images for  
485 analysis, as well as the file extensions corresponding to the brightfield and fluorescence images,  
486 which are essential for the subsequent steps. The script then iterates through each pair of brightfield  
487 and fluorescent images prompting the user to define two points on the brightfield image, which serve  
488 as the start and end positions between which to create concentric circular regions (80) on the  
489 corresponding fluorescence image. The script employs the image processing techniques described  
490 in Table S5 to quantify integrated fluorescence of the entire image and that within each region, as a  
491 surrogate for the total number of immune cells and the number at each spatial location, respectively  
492 and generates output files containing this information. Integrated fluorescence within the first zone  
493 (the wound site) and distance from the site of tailfin transection of the zone in which the maximal  
494 integrated fluorescence (a surrogate for the highest cell numbers) was detected (identified manually)  
495 were used as measures of immune cell recruitment for each zebrafish larva. The number of cells  
496 recruited to the site of hindbrain *M. marinum* infection was quantified by manual counting.

## 497 **Genotyping by next generation sequencing**

### 498 **Genomic DNA extraction**

499 Genomic DNA was extracted from anaesthetised individual zebrafish larvae using the modified hot  
500 sodium hydroxide and Tris (HotSHOT) method as previously described (73, 83). Briefly, larvae in  
501 96-well plates were incubated in 50 µl base solution (25 mM KOH, 0.2 mM EDTA in water) at 95°C  
502 for 30 min then cooled to room temperature, before addition of 50 µl neutralization solution (40 mM  
503 Tris-HCL in water).

### 504 **PCR**

505 Extracted DNA (2 µl per 50 µl reaction) was subjected to PCR using Phusion High-Fidelity DNA  
506 Polymerase (New England Biolabs) (98°C for 30 seconds (s), once only, 40 cycles of 98°C for 10 s,  
507 59°C for 30 s, 72°C for 20 s, 72°C for 10 minutes, once only). Sequences and genomic positions of  
508 the primers used are provided in Table S3. Successful amplification of a single product of  
509 approximately 300 bp was verified by 2% agarose (Bioline) Tris-borate-EDTA (TBE) containing  
510 Redsafe (ChemBio) gel electrophoresis. PCR products were purified using ExoSAP-IT Express  
511 (ThermoFisher), concentration of purified DNA determined by Nanodrop spectrophotometer  
512 (ThermoFisher) and samples diluted to 15-25 ng/µl for sequencing.

### 513 **Next generation sequencing and data analysis**

514 Sequencing was performed by the UCL Fish Genomic Service using the MiSeq Reagent Kit v2 (300-  
515 cycles) (Illumina) and the MiSeq system (Illumina) in paired end mode, according to the  
516 manufacturer's instructions. Sequencing data were received as two FASTQ files (forward and



517 reverse) for each sample. Visual sequence analysis was performed using Geneious 10.2.6  
518 (<https://www.geneious.com>) for initial verification of successful genome editing close to the PAM site.  
519 Objective quantitation of the proportion of reads mutated and predicted to be frameshifted was  
520 achieved using the ampliCan R package (84), which utilizes the FASTQ files and a metadata file  
521 providing the amplicon, protospacer adjacent motif (PAM) and primer sequences (Table S3) and  
522 sample information, as previously described (73). AmpliCan was run with default parameters, with  
523 the exception that `min_freq = 0.005` (mutations at a frequency below this threshold were considered  
524 a sequencing error) and `average_quality = 25`. Mutations present in uninjected or scrambled RNP  
525 injected control samples were not included as Cas9 induced mutations.

## 526 **Statistical analysis**

527 Statistical analysis was performed using GraphPad Prism 9.3.1 for Windows (GraphPad Software)  
528 and R3.6.3. Chi-squared tests were used to identify outlier genes statistically enriched in  
529 transcriptomic data from TST samples compared to saline samples, with no correction for multiple  
530 testing to avoid type 2 error. Spearman rank correlation was used to determine the strength of  
531 relationship between TST transcriptome gene expression and TB disease severity (two-tailed),  
532 transcript levels of upstream regulator target gene modules and TST random gene modules (one-  
533 tailed, positive correlation only) and mean expression of transcriptional modules in TST  
534 transcriptomic data with severity of TB disease (two-tailed). The Benjamini-Hochberg correction  
535 method for multiple comparisons was used to identify upstream regulator target gene modules with  
536 average correlation coefficients significantly higher than the mean of the distribution of equivalent  
537 sized randomly selected gene modules by  $\geq 2$  SD (Z score  $\geq 2$ ) with false discovery rate  $< 0.05$ .  
538 Survival of *stat2* CRISPR and control zebrafish larvae was compared using a log-rank (Mantel-  
539 Cox) test; a p value  $< 0.05$  was considered significant. On scatter plots horizontal lines represent  
540 median values and error bars indicate the interquartile range. On box and whisker plots horizontal  
541 lines represent median values, box limits indicate the interquartile range and whiskers extend  
542 between the 5th and 95th percentiles of the data. Two-tailed Mann-Whitney tests were used for two  
543 group comparisons of unpaired data; a p value  $< 0.05$  was considered significant. Where p values  
544 are not presented on graphs, \* denotes  $p < 0.05$ .

## 545 **REFERENCES AND NOTES**

- 546 1. A. K. Coussens, S. M. A. Zaidi, B. W. Allwood, P. K. Dewan, G. Gray, M. Kohli, T. Kredo, B. J.  
547 Marais, G. B. Marks, L. Martinez, M. Ruhwald, T. J. Scriba, J. A. Seddon, P. Tisile, D. F. Warner, R.  
548 J. Wilkinson, H. Esmail, R. M. G. J. Houben, International Consensus for Early TB (ICE-TB) group,  
549 Classification of early tuberculosis states to guide research for improved care and prevention: an  
550 international Delphi consensus exercise. *Lancet Respir. Med.* **12**, 484–498 (2024).
- 551 2. A. M. Cadena, S. M. Fortune, J. L. Flynn, Heterogeneity in tuberculosis. *Nat. Rev. Immunol.* **17**,  
552 691–702 (2017).
- 553 3. S. H. E. Kaufmann, C. Lange, M. Rao, K. N. Balaji, M. Lotze, M. Schito, A. I. Zumla, M. Maeurer,  
554 Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review.  
555 *Lancet Respir. Med.* **2**, 301–320 (2014).
- 556 4. G. S. Tomlinson, T. J. Cashmore, P. T. G. Elkington, J. Yates, R. J. Lehloeny, J. Tsang, M.  
557 Brown, R. F. Miller, K. Dheda, D. R. Katz, B. M. Chain, M. Noursadeghi, Transcriptional profiling of  
558 innate and adaptive human immune responses to mycobacteria in the tuberculin skin test. *Eur. J.*  
559 *Immunol.* **41**, 3253–3260 (2011).
- 560 5. L. C. K. Bell, G. Pollara, M. Pascoe, G. S. Tomlinson, R. J. Lehloeny, J. Roe, R. Meldau, R. F.  
561 Miller, A. Ramsay, B. M. Chain, K. Dheda, M. Noursadeghi, In Vivo Molecular Dissection of the  
562 Effects of HIV-1 in Active Tuberculosis. *PLoS Pathog.* **12**, e1005469 (2016).
- 563 6. M.-J. Kim, H. C. Wainwright, M. Locketz, L.-G. Bekker, G. B. Walther, C. Dittrich, A. Visser, W.  
564 Wang, F.-F. Hsu, U. Wiehart, L. Tsenova, G. Kaplan, D. G. Russell, Caseation of human tuberculosis  
565 granulomas correlates with elevated host lipid metabolism. *EMBO Mol. Med.* **2**, 258–274 (2010).
- 566 7. L. Ramakrishnan, The zebrafish guide to tuberculosis immunity and treatment. *Cold Spring Harb.*



- 567 *Symp. Quant. Biol.* **78**, 179–192 (2013).
- 568 8. G. Pollara, C. T. Turner, J. Rosenheim, A. Chandran, L. C. K. Bell, A. Khan, A. Patel, L. F. Peralta,  
569 A. Folino, A. Akarca, C. Venturini, T. Baker, S. Ecker, F. L. M. Ricciardolo, T. Marafioti, C. Ugarte-  
570 Gil, D. A. J. Moore, B. M. Chain, G. S. Tomlinson, M. Noursadeghi, Exaggerated IL-17A activity in  
571 human in vivo recall responses discriminates active tuberculosis from latent infection and cured  
572 disease. *Sci. Transl. Med.* **13**, eabg7673 (2021).
- 573 9. A. P. Ralph, M. Ardian, A. Wiguna, G. P. Maguire, N. G. Becker, G. Drogumuller, M. J. Wilks, G.  
574 Waramori, E. Tjitra, null Sandjaja, E. Kenagalem, G. J. Pontororing, N. M. Anstey, P. M. Kelly, A  
575 simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary  
576 tuberculosis. *Thorax* **65**, 863–869 (2010).
- 577 10. D. L. Roden, G. W. Sewell, A. Lobley, A. P. Levine, A. M. Smith, A. W. Segal, ZODET: software  
578 for the identification, analysis and visualisation of outlier genes in microarray expression data. *PLoS*  
579 *One* **9**, e81123 (2014).
- 580 11. A. Chandran, J. Rosenheim, G. Nageswaran, L. Swadling, G. Pollara, R. K. Gupta, A. R. Burton,  
581 J. A. Guerra-Assunção, A. Woolston, T. Ronel, C. Pade, J. M. Gibbons, B. Sanz-Magallon Duque  
582 De Estrada, M. Robert de Massy, M. Whelan, A. Semper, T. Brooks, D. M. Altmann, R. J. Boyton,  
583 Á. McKnight, G. Captur, C. Manisty, T. A. Treibel, J. C. Moon, G. S. Tomlinson, M. K. Maini, B. M.  
584 Chain, M. Noursadeghi, COVIDsortium Investigators, Rapid synchronous type 1 IFN and virus-  
585 specific T cell responses characterize first wave non-severe SARS-CoV-2 infections. *Cell Rep. Med.*  
586 **3**, 100557 (2022).
- 587 12. R. L. Kinsella, D. X. Zhu, G. A. Harrison, A. E. Mayer Bridwell, J. Prusa, S. M. Chavez, C. L.  
588 Stallings, Perspectives and Advances in the Understanding of Tuberculosis. *Annu. Rev. Pathol.*  
589 *Mech. Dis.* **16**, 377–408 (2021).
- 590 13. F. Paduano, E. Gaudio, A. A. Mensah, S. Pinton, F. Bertoni, F. Trapasso, T-Cell  
591 Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways. *Front.*  
592 *Oncol.* **8**, 317 (2018).
- 593 14. F. McNab, K. Mayer-Barber, A. Sher, A. Wack, A. O’Garra, Type I interferons in infectious  
594 disease. *Nat. Rev. Immunol.* **15**, 87–103 (2015).
- 595 15. C. Langevin, E. Aleksejeva, G. Passoni, N. Palha, J.-P. Levraud, P. Boudinot, The antiviral innate  
596 immune response in fish: evolution and conservation of the IFN system. *J. Mol. Biol.* **425**, 4904–  
597 4920 (2013).
- 598 16. J.-P. Levraud, L. Jouneau, V. Briolat, V. Laghi, P. Boudinot, IFN-Stimulated Genes in Zebrafish  
599 and Humans Define an Ancient Arsenal of Antiviral Immunity. *J. Immunol. Baltim. Md 1950* **203**,  
600 3361–3373 (2019).
- 601 17. K. Blaszczyk, H. Nowicka, K. Kostyrko, A. Antonczyk, J. Wesoly, H. A. R. Bluysen, The unique  
602 role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. *Cytokine Growth*  
603 *Factor Rev.* **29**, 71–81 (2016).
- 604 18. A. Begitt, M. Droscher, T. Meyer, C. D. Schmid, M. Baker, F. Antunes, K.-P. Knobloch, M. R.  
605 Owen, R. Naumann, T. Decker, U. Vinkemeier, STAT1-cooperative DNA binding distinguishes type  
606 1 from type 2 interferon signaling. *Nat. Immunol.* **15**, 168–176 (2014).
- 607 19. J. W. Schoggins, Interferon-Stimulated Genes: What Do They All Do? *Annu. Rev. Virol.* **6**, 567–  
608 584 (2019).
- 609 20. H. Clay, J. M. Davis, D. Beery, A. Huttenlocher, S. E. Lyons, L. Ramakrishnan, Dichotomous role  
610 of the macrophage in early *Mycobacterium marinum* infection of the zebrafish. *Cell Host Microbe* **2**,  
611 29–39 (2007).

*Protective type I interferon responses in mycobacterial infection*

- 612 21. A. J. Pagán, C.-T. Yang, J. Cameron, L. E. Swaim, F. Ellett, G. J. Lieschke, L. Ramakrishnan,  
613 Myeloid Growth Factors Promote Resistance to Mycobacterial Infection by Curtailing Granuloma  
614 Necrosis through Macrophage Replenishment. *Cell Host Microbe* **18**, 15–26 (2015).
- 615 22. R. D. Berg, S. Levitte, M. P. O’Sullivan, S. M. O’Leary, C. J. Cambier, J. Cameron, K. K. Takaki,  
616 C. B. Moens, D. M. Tobin, J. Keane, L. Ramakrishnan, Lysosomal Disorders Drive Susceptibility to  
617 Tuberculosis by Compromising Macrophage Migration. *Cell* **165**, 139–152 (2016).
- 618 23. C.-T. Yang, C. J. Cambier, J. M. Davis, C. J. Hall, P. S. Crosier, L. Ramakrishnan, Neutrophils  
619 exert protection in the early tuberculous granuloma by oxidative killing of mycobacteria  
620 phagocytosed from infected macrophages. *Cell Host Microbe* **12**, 301–312 (2012).
- 621 24. P. M. Elks, S. Brizee, M. van der Vaart, S. R. Walmsley, F. J. van Eeden, S. A. Renshaw, A. H.  
622 Meijer, Hypoxia inducible factor signaling modulates susceptibility to mycobacterial infection via a  
623 nitric oxide dependent mechanism. *PLoS Pathog.* **9**, e1003789 (2013).
- 624 25. I. Rauch, M. Müller, T. Decker, The regulation of inflammation by interferons and their STATs.  
625 *JAK-STAT* **2**, e23820 (2013).
- 626 26. S. A. Renshaw, C. A. Loynes, D. M. I. Trushell, S. Elworthy, P. W. Ingham, M. K. B. Whyte, A  
627 transgenic zebrafish model of neutrophilic inflammation. *Blood* **108**, 3976–3978 (2006).
- 628 27. C. Gray, C. A. Loynes, M. K. B. Whyte, D. C. Crossman, S. A. Renshaw, T. J. A. Chico,  
629 Simultaneous intravital imaging of macrophage and neutrophil behaviour during inflammation using  
630 a novel transgenic zebrafish. *Thromb. Haemost.* **105**, 811–819 (2011).
- 631 28. F. Ellett, L. Pase, J. W. Hayman, A. Andrianopoulos, G. J. Lieschke, mpeg1 promoter transgenes  
632 direct macrophage-lineage expression in zebrafish. *Blood* **117**, e49-56 (2011).
- 633 29. M. P. R. Berry, C. M. Graham, F. W. McNab, Z. Xu, S. A. A. Bloch, T. Oni, K. A. Wilkinson, R.  
634 Banchereau, J. Skinner, R. J. Wilkinson, C. Quinn, D. Blankenship, R. Dhawan, J. J. Cush, A. Mejias,  
635 O. Ramilo, O. M. Kon, V. Pascual, J. Banchereau, D. Chaussabel, A. O’Garra, An interferon-  
636 inducible neutrophil-driven blood transcriptional signature in human tuberculosis. *Nature* **466**, 973–  
637 977 (2010).
- 638 30. C. I. Bloom, C. M. Graham, M. P. R. Berry, K. A. Wilkinson, T. Oni, F. Rozakeas, Z. Xu, J.  
639 Rossello-Urgell, D. Chaussabel, J. Banchereau, V. Pascual, M. Lipman, R. J. Wilkinson, A. O’Garra,  
640 Detectable Changes in The Blood Transcriptome Are Present after Two Weeks of Antituberculosis  
641 Therapy. *PLOS ONE* **7**, e46191 (2012).
- 642 31. T. H. M. Ottenhoff, R. H. Dass, N. Yang, M. M. Zhang, H. E. E. Wong, E. Sahiratmadja, C. C.  
643 Khor, B. Alisjahbana, R. van Crevel, S. Marzuki, M. Seielstad, E. van de Vosse, M. L. Hibberd,  
644 Genome-Wide Expression Profiling Identifies Type 1 Interferon Response Pathways in Active  
645 Tuberculosis. *PLOS ONE* **7**, e45839 (2012).
- 646 32. K. D. Mayer-Barber, B. B. Andrade, D. L. Barber, S. Hieny, C. G. Feng, P. Caspar, S. Oland, S.  
647 Gordon, A. Sher, Innate and Adaptive Interferons Suppress IL-1 $\alpha$  and IL-1 $\beta$  Production by Distinct  
648 Pulmonary Myeloid Subsets during Mycobacterium tuberculosis Infection. *Immunity* **35**, 1023–1034  
649 (2011).
- 650 33. K. D. Mayer-Barber, B. B. Andrade, S. D. Oland, E. P. Amaral, D. L. Barber, J. Gonzales, S. C.  
651 Derrick, R. Shi, N. P. Kumar, W. Wei, X. Yuan, G. Zhang, Y. Cai, S. Babu, M. Catalfamo, A. M.  
652 Salazar, L. E. Via, C. E. Barry, A. Sher, Host-directed therapy of tuberculosis based on interleukin-  
653 1 and type I interferon crosstalk. *Nature* **511**, 99–103 (2014).
- 654 34. D. X. Ji, L. H. Yamashiro, K. J. Chen, N. Mukaida, I. Kramnik, K. H. Darwin, R. E. Vance, Type I  
655 interferon-driven susceptibility to Mycobacterium tuberculosis is mediated by IL-1Ra. *Nat. Microbiol.*  
656 **4**, 2128–2135 (2019).

*Protective type I interferon responses in mycobacterial infection*

- 657 35. D. I. Kotov, O. V. Lee, S. A. Fattinger, C. A. Langner, J. V. Guillen, J. M. Peters, A. Moon, E. M.  
658 Burd, K. C. Witt, D. B. Stetson, D. L. Jaye, B. D. Bryson, R. E. Vance, Early cellular mechanisms of  
659 type I interferon-driven susceptibility to tuberculosis. *Cell* **186**, 5536-5553.e22 (2023).
- 660 36. L. Moreira-Teixeira, K. Mayer-Barber, A. Sher, A. O'Garra, Type I interferons in tuberculosis: Foe  
661 and occasionally friend. *J. Exp. Med.* **215**, 1273–1285 (2018).
- 662 37. I. Kramnik, G. Beamer, Mouse models of human TB pathology: roles in the analysis of necrosis  
663 and the development of host-directed therapies. *Semin. Immunopathol.* **38**, 221–237 (2016).
- 664 38. S. Giosué, M. Casarini, L. Alemanno, G. Galluccio, P. Mattia, G. Pedicelli, L. Rebek, A. Bisetti,  
665 F. Ameglio, Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. *Am. J.*  
666 *Respir. Crit. Care Med.* **158**, 1156–1162 (1998).
- 667 39. P. Zarogoulidis, I. Kioumis, N. Papanas, K. Manika, T. Kontakiotis, A. Papagianis, K.  
668 Zarogoulidis, The effect of combination IFN-alpha-2a with usual antituberculosis chemotherapy in  
669 non-responding tuberculosis and diabetes mellitus: a case report and review of the literature. *J.*  
670 *Chemother.* **24**, 173–177 (2012).
- 671 40. D. Mansoori, S. Tavana, M. Mirsaiedi, M. Yazdanpanah, H. Sohrabpour, The Efficacy of  
672 Interferon- $\alpha$  in the Treatment of Multidrug Resistant Tuberculosis. *TANAFFOS* **1**, 29–34 (2002).
- 673 41. Y. E. Liu, P. A. Darrah, J. J. Zeppa, M. Kamath, F. Laboune, D. C. Douek, P. Maiello, M.  
674 Roederer, J. L. Flynn, R. A. Seder, P. Khatri, Blood transcriptional correlates of BCG-induced  
675 protection against tuberculosis in rhesus macaques. *Cell Rep. Med.* **4**, 101096 (2023).
- 676 42. L. B. Tezera, M. K. Bielecka, A. Chancellor, M. T. Reichmann, B. A. Shammari, P. Brace, A.  
677 Batty, A. Tocheva, S. Jogai, B. G. Marshall, M. Tebruegge, S. N. Jayasinghe, S. Mansour, P. T.  
678 Elkington, B. Aldridge, Ed. Dissection of the host-pathogen interaction in human tuberculosis using  
679 a bioengineered 3-dimensional model. *eLife* **6**, e21283 (2017).
- 680 43. V. Torraca, C. Cui, R. Boland, J.-P. Bebelman, A. M. van der Sar, M. J. Smit, M. Siderius, H. P.  
681 Spaik, A. H. Meijer, The CXCR3-CXCL11 signaling axis mediates macrophage recruitment and  
682 dissemination of mycobacterial infection. *Dis. Model. Mech.* **8**, 253–269 (2015).
- 683 44. J. M. Davis, H. Clay, J. L. Lewis, N. Ghori, P. Herbomel, L. Ramakrishnan, Real-time visualization  
684 of mycobacterium-macrophage interactions leading to initiation of granuloma formation in zebrafish  
685 embryos. *Immunity* **17**, 693–702 (2002).
- 686 45. D. M. Tobin, F. J. Roca, S. F. Oh, R. McFarland, T. W. Vickery, J. P. Ray, D. C. Ko, Y. Zou, N.  
687 D. Bang, T. T. H. Chau, J. C. Vary, T. R. Hawn, S. J. Dunstan, J. J. Farrar, G. E. Thwaites, M.-C.  
688 King, C. N. Serhan, L. Ramakrishnan, Host genotype-specific therapies can optimize the  
689 inflammatory response to mycobacterial infections. *Cell* **148**, 434–446 (2012).
- 690 46. A.-L. Neehus, B. Carey, M. Landekic, P. Panikulam, G. Deutsch, M. Ogishi, C. A. Arango-Franco,  
691 Q. Philippot, M. Modaresi, I. Mohammadzadeh, M. Corcini Berndt, D. Rinchai, T. Le Voyer, J. Rosain,  
692 M. Momenilandi, M. Martin-Fernandez, T. Khan, J. Bohlen, J. E. Han, A. Deslys, M. Bernard, T.  
693 Gajardo-Carrasco, C. Soudée, C. Le Floch, M. Migaud, Y. Seeleuthner, M.-S. Jang, E. Nikolouli, S.  
694 Seyedpour, H. Begueret, J.-F. Emile, P. Le Guen, G. Tavazzi, C. N. J. Colombo, F. C. Marzani, M.  
695 Angelini, F. Trespidi, S. Ghirardello, N. Alipour, A. Molitor, R. Carapito, M. Mazloomrezaei, H. Rokni-  
696 Zadeh, M. Changi-Ashtiani, C. Brouzes, P. Vargas, A. Borghesi, N. Lachmann, S. Bahram, B.  
697 Crestani, S. Pahari, L. S. Schlesinger, N. Marr, D. Bugonovic, S. Boisson-Dupuis, V. Béziat, L. Abel,  
698 R. Borie, L. R. Young, R. Deterding, M. Shahrooei, N. Rezaei, N. Parvaneh, D. Craven, P. Gros, D.  
699 Malo, F. E. Sepulveda, L. M. Nogee, N. Aladjidi, B. C. Trapnell, J.-L. Casanova, J. Bustamante,  
700 Human inherited CCR2 deficiency underlies progressive polycystic lung disease. *Cell* **187**, 390-  
701 408.e23 (2024).
- 702 47. K. B. Walters, J. M. Green, J. C. Surfus, S. K. Yoo, A. Huttenlocher, Live imaging of neutrophil

*Protective type I interferon responses in mycobacterial infection*

- 703 motility in a zebrafish model of WHIM syndrome. *Blood* **116**, 2803–2811 (2010).
- 704 48. M. H. Lehmann, L. E. Torres-Domínguez, P. J. R. Price, C. Brandmüller, C. J. Kirschning, G.  
705 Sutter, CCL2 expression is mediated by type I IFN receptor and recruits NK and T cells to the lung  
706 during MVA infection. *J. Leukoc. Biol.* **99**, 1057–1064 (2016).
- 707 49. M. Buttman, C. Merzyn, P. Rieckmann, Interferon-beta induces transient systemic IP-  
708 10/CXCL10 chemokine release in patients with multiple sclerosis. *J. Neuroimmunol.* **156**, 195–203  
709 (2004).
- 710 50. C. J. Cambier, K. K. Takaki, R. P. Larson, R. E. Hernandez, D. M. Tobin, K. B. Urdahl, C. L.  
711 Cosma, L. Ramakrishnan, Mycobacteria manipulate macrophage recruitment through coordinated  
712 use of membrane lipids. *Nature* **505**, 218–222 (2014).
- 713 51. L. Abel, J. Fellay, D. W. Haas, E. Schurr, G. Srikrishna, M. Urbanowski, N. Chaturvedi, S.  
714 Srinivasan, D. H. Johnson, W. R. Bishai, Genetics of human susceptibility to active and latent  
715 tuberculosis: present knowledge and future perspectives. *Lancet Infect. Dis.* **18**, e64–e75 (2018).
- 716 52. A. Khadela, V. P. Chavda, H. Postwala, Y. Shah, P. Mistry, V. Apostolopoulos, Epigenetics in  
717 Tuberculosis: Immunomodulation of Host Immune Response. *Vaccines* **10**, 1740 (2022).
- 718 53. A. L. Jacobs, Infective dose in pulmonary tuberculosis. *Tubercle* **22**, 266–271 (1941).
- 719 54. C. R. Plumlee, F. J. Duffy, B. H. Gern, J. L. Delahaye, S. B. Cohen, C. R. Stoltzfus, T. R. Rustad,  
720 S. G. Hansen, M. K. Axthelm, L. J. Picker, J. D. Aitchison, D. R. Sherman, V. V. Ganusov, M. Y.  
721 Gerner, D. E. Zak, K. B. Urdahl, Ultra-low Dose Aerosol Infection of Mice with Mycobacterium  
722 tuberculosis More Closely Models Human Tuberculosis. *Cell Host Microbe* **29**, 68-82.e5 (2021).
- 723 55. J.-L. Casanova, M. S. Anderson, Unlocking life-threatening COVID-19 through two types of  
724 inborn errors of type I IFNs. *J. Clin. Invest.* **133**, e166283.
- 725 56. P. Elkington, T. Shiomi, R. Breen, R. K. Nuttall, C. A. Ugarte-Gil, N. F. Walker, L. Saraiva, B.  
726 Pedersen, F. Mauri, M. Lipman, D. R. Edwards, B. D. Robertson, J. D'Armiento, J. S. Friedland,  
727 MMP-1 drives immunopathology in human tuberculosis and transgenic mice. *J. Clin. Invest.* **121**,  
728 1827–1833 (2011).
- 729 57. L. Guglielmetti, A. Cazzadori, M. Conti, F. Boccafoglio, A. Vella, R. Ortolani, E. Concia,  
730 Lymphocyte subpopulations in active tuberculosis: association with disease severity and the QFT-  
731 GIT assay. *Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis.* **17**, 825–828 (2013).
- 732 58. J. O. Jurado, V. Pasquinelli, I. B. Alvarez, D. Peña, A. I. Rovetta, N. L. Tateosian, H. E. Romeo,  
733 R. M. Musella, D. Palmero, H. E. Chuluyán, V. E. García, IL-17 and IFN- $\gamma$  expression in lymphocytes  
734 from patients with active tuberculosis correlates with the severity of the disease. *J. Leukoc. Biol.* **91**,  
735 991–1002 (2012).
- 736 59. Z. Hasan, B. Jamil, J. Khan, R. Ali, M. A. Khan, N. Nasir, M. S. Yusuf, S. Jamil, M. Irfan, R.  
737 Hussain, Relationship between circulating levels of IFN-gamma, IL-10, CXCL9 and CCL2 in  
738 pulmonary and extrapulmonary tuberculosis is dependent on disease severity. *Scand. J. Immunol.*  
739 **69**, 259–267 (2009).
- 740 60. J. Roe, C. Venturini, R. K. Gupta, C. Gurry, B. M. Chain, Y. Sun, J. Southern, C. Jackson, M. C.  
741 Lipman, R. F. Miller, A. R. Martineau, I. Abubakar, M. Noursadeghi, Blood Transcriptomic  
742 Stratification of Short-term Risk in Contacts of Tuberculosis. *Clin. Infect. Dis. Off. Publ. Infect. Dis.*  
743 *Soc. Am.* **70**, 731–737 (2020).
- 744 61. N. L. Bray, H. Pimentel, P. Melsted, L. Pachter, Near-optimal probabilistic RNA-seq  
745 quantification. *Nat. Biotechnol.* **34**, 525–527 (2016).



*Protective type I interferon responses in mycobacterial infection*

- 746 62. C. Sonesson, M. I. Love, M. D. Robinson, Differential analyses for RNA-seq: transcript-level  
747 estimates improve gene-level inferences. *F1000Research* **4**, 1521 (2015).
- 748 63. S. Durinck, P. T. Spellman, E. Birney, W. Huber, Mapping identifiers for the integration of  
749 genomic datasets with the R/Bioconductor package biomaRt. *Nat. Protoc.* **4**, 1184–1191 (2009).
- 750 64. J. T. Leek, W. E. Johnson, H. S. Parker, A. E. Jaffe, J. D. Storey, The sva package for removing  
751 batch effects and other unwanted variation in high-throughput experiments. *Bioinforma. Oxf. Engl.*  
752 **28**, 882–883 (2012).
- 753 65. H. Fang, B. Knezevic, K. L. Burnham, J. C. Knight, XGR software for enhanced interpretation of  
754 genomic summary data, illustrated by application to immunological traits. *Genome Med.* **8**, 129  
755 (2016).
- 756 66. C. T. Turner, J. Brown, E. Shaw, I. Uddin, E. Tsaliki, J. K. Roe, G. Pollara, Y. Sun, J. M. Heather,  
757 M. Lipman, B. Chain, M. Noursadeghi, Persistent T Cell Repertoire Perturbation and T Cell  
758 Activation in HIV After Long Term Treatment. *Front. Immunol.* **12**, 634489 (2021).
- 759 67. M. Jacomy, T. Venturini, S. Heymann, M. Bastian, ForceAtlas2, a continuous graph layout  
760 algorithm for handy network visualization designed for the Gephi software. *PloS One* **9**, e98679  
761 (2014).
- 762 68. W. R. Swindell, X. Xing, P. E. Stuart, C. S. Chen, A. Aphale, R. P. Nair, J. J. Voorhees, J. T.  
763 Elder, A. Johnston, J. E. Gudjonsson, Heterogeneity of inflammatory and cytokine networks in  
764 chronic plaque psoriasis. *PloS One* **7**, e34594 (2012).
- 765 69. T. Hulsen, J. de Vlieg, W. Alkema, BioVenn - a web application for the comparison and  
766 visualization of biological lists using area-proportional Venn diagrams. *BMC Genomics* **9**, 488 (2008).
- 767 70. C. Nusslein-Volhard, *Zebrafish: A Practical Approach* R. Dahm, Ed. (Oxford University Press,  
768 Oxford, 1 edition., 2002).
- 769 71. G. Maarifi, N. Smith, S. Maillet, O. Moncorgé, C. Chamontin, J. Edouard, F. Sohm, F. P. Blanchet,  
770 J.-P. Herbeuval, G. Lutfalla, J.-P. Levrud, N. J. Arhel, S. Nisole, TRIM8 is required for virus-induced  
771 IFN response in human plasmacytoid dendritic cells. *Sci. Adv.* **5**, eaax3511 (2019).
- 772 72. K. Voelz, R. L. Gratacap, R. T. Wheeler, A zebrafish larval model reveals early tissue-specific  
773 innate immune responses to *Mucor circinelloides*. *Dis. Model. Mech.* **8**, 1375–1388 (2015).
- 774 73. F. Kroll, G. T. Powell, M. Ghosh, G. Gestri, P. Antinucci, T. J. Hearn, H. Tunbak, S. Lim, H. W.  
775 Dennis, J. M. Fernandez, D. Whitmore, E. Dreosti, S. W. Wilson, E. J. Hoffman, J. Rihel, S. C. Ekker,  
776 D. Y. Stainier, D. Balciunas, Eds. A simple and effective F0 knockout method for rapid screening of  
777 behaviour and other complex phenotypes. *eLife* **10**, e59683 (2021).
- 778 74. D. Aggad, M. Mazel, P. Boudinot, K. E. Mogensen, O. J. Hamming, R. Hartmann, S. Kotenko,  
779 P. Herbomel, G. Lutfalla, J.-P. Levrud, The two groups of zebrafish virus-induced interferons signal  
780 via distinct receptors with specific and shared chains. *J. Immunol. Baltim. Md 1950* **183**, 3924–3931  
781 (2009).
- 782 75. K. Takaki, J. M. Davis, K. Winglee, L. Ramakrishnan, Evaluation of the pathogenesis and  
783 treatment of *Mycobacterium marinum* infection in zebrafish. *Nat. Protoc.* **8**, 1114–1124 (2013).
- 784 76. L. M. van Leeuwen, M. van der Kuip, S. A. Youssef, A. de Bruin, W. Bitter, A. M. van Furth, A.  
785 M. van der Sar, Modeling tuberculous meningitis in zebrafish using *Mycobacterium marinum*. *Dis.*  
786 *Model. Mech.* **7**, 1111–1122 (2014).
- 787 77. E. L. Benard, A. M. van der Sar, F. Ellett, G. J. Lieschke, H. P. Spaink, A. H. Meijer, Infection of  
788 zebrafish embryos with intracellular bacterial pathogens. *J. Vis. Exp. JoVE* (2012),

*Protective type I interferon responses in mycobacterial infection*

789 doi:10.3791/3781.

790 78. R. N. Wilkinson, S. Elworthy, P. W. Ingham, F. J. M. van Eeden, A method for high-throughput  
791 PCR-based genotyping of larval zebrafish tail biopsies. *BioTechniques* **55**, 314–316 (2013).

792 79. D. R. Stirling, O. Suleyman, E. Gil, P. M. Elks, V. Torraca, M. Noursadeghi, G. S. Tomlinson,  
793 Analysis tools to quantify dissemination of pathology in zebrafish larvae. *Sci. Rep.* **10**, 3149 (2020).

794 80. D. A. Sholl, Dendritic organization in the neurons of the visual and motor cortices of the cat. *J.*  
795 *Anat.* **87**, 387–406 (1953).

796 81. S. van der Walt, S. C. Colbert, G. Varoquaux, The NumPy Array: A Structure for Efficient  
797 Numerical Computation. *Comput. Sci. Eng.* **13**, 22–30 (2011).

798 82. S. van der Walt, J. L. Schönberger, J. Nunez-Iglesias, F. Boulogne, J. D. Warner, N. Yager, E.  
799 Gouillart, T. Yu, scikit-image contributors, scikit-image: image processing in Python. *PeerJ* **2**, e453  
800 (2014).

801 83. N. D. Meeker, S. A. Hutchinson, L. Ho, N. S. Trede, Method for isolation of PCR-ready genomic  
802 DNA from zebrafish tissues. *BioTechniques* **43**, 610, 612, 614 (2007).

803 84. K. Labun, X. Guo, A. Chavez, G. Church, J. A. Gagnon, E. Valen, Accurate analysis of genuine  
804 CRISPR editing events with ampliCan. *Genome Res.* **29**, 843–847 (2019).

805

806 **ACKNOWLEDGEMENTS**

807 We thank Michelle Berin and Victoria Dean (Clinical Research Nurses, UCL Division of Infection and  
808 Immunity) and Mylah Ramirez (Research Nurse, Barts Health NHS Trust) for support with research  
809 governance, participant recruitment and sample collection. We thank the UCL Zebrafish Facility staff,  
810 particularly Heather Callaway, Jenna Hakkesteege, Karen Dunford, Carole Wilson and Elise  
811 Hitchcock for maintenance of the zebrafish lines used in this study, especially during the first wave  
812 of the COVID-19 pandemic. We thank UCL Genomics for library preparation and sequencing of  
813 samples for transcriptional profiling ([www.ucl.ac.uk/child-health/research/genetics-and-genomic-medicine/ucl-genomics](http://www.ucl.ac.uk/child-health/research/genetics-and-genomic-medicine/ucl-genomics)). We thank Alex Lubin and Katie-Jo Miller for next generation sequencing of  
814 zebrafish samples for genotyping. This work has benefited from the facilities and expertise of  
815 CELPHEDIA-TEFOR, UAR2010 TEFOR Paris-Saclay (TEFOR Infrastructure - Investissement  
816 d'avenir - ANR-II-INBS-0014) and from the Recombinant Protein Platform of the Institut Pasteur,  
817 Paris.  
818

819 **FUNDING**

820 UK Medical Research Council Clinician Scientist Fellowship MR/N007727/1 (GST)

821 Wellcome Trust Investigator Award 207511/Z/17/Z (MN)

822 Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society 105570/Z/14/Z  
823 (PME)

824 Fondation pour la Recherche Medicale grant EQU202203014646 (J-PL)

825 National Institute of Health Research Biomedical Research Centre Funding to University College  
826 Hospitals NHS Foundation Trust and University College London (GST, MN)

827 This research was funded in whole, or in part, by the Wellcome Trust [207511/Z/17/Z,  
828 105570/Z/14/Z]. For the purpose of Open Access, the author has applied a CC BY public copyright  
829 licence to any Author Accepted Manuscript version arising from this submission.

830 **AUTHOR CONTRIBUTIONS**

831 Conceived the study: GST, MN

832 Collected the data: ASS, BSMDDE, JR, ET, GP, J-PL, GST

*Protective type I interferon responses in mycobacterial infection*

833 Provided resources or analysis tools: ASS, BSMDDDE, JR, CTT, MCIL, HK, GP, PME, EMP, J-PL,  
834 MN, GST

835 Performed the data analysis / interpretation: ASS, BSMDDDE, JR, CTT, GP, PME, EMP, J-PL, MN,  
836 GST

837 Prepared the manuscript draft: GST, ASS, BSMDDDE

838 All authors reviewed and contributed to the final manuscript.

839 **COMPETING INTERESTS**


840 The authors declare that they have no competing interests.

841 **DATA AND MATERIALS AVAILABILITY**

842 Human RNAseq data are already available in the ArrayExpress repository under accession number  
843 E-MTAB-6816. Zebrafish RNAseq data will be made available in ArrayExpress at the time of peer  
844 reviewed publication of the manuscript. The source code and manual for QuantiFish software used  
845 for analysis of bacterial burden and dissemination in zebrafish larvae are available at  
846 <https://github.com/DavidStirling/QuantiFish>. The ImageJ macro used to generate montages from the  
847 Hermes images and source code and manual for the Python script used for analysis of steady state  
848 cell numbers and cellular recruitment in zebrafish are available at  
849 [https://github.com/AndSzyShe/particle\\_analysis](https://github.com/AndSzyShe/particle_analysis). Source data for figure panels with fewer than 20  
850 data points are available in Data file S1.

851

852 FIGURES



853


854 **Fig. 1. Reduced type I interferon activity in the TST transcriptome is associated with**  
 855 **increased severity of human TB disease. (A)** Frequency distribution of the correlation coefficients  
 856 for the relationship between the abundance of each of the 3222 transcripts within the tuberculin skin  
 857 test (TST) transcriptome derived from 51 individuals with pulmonary tuberculosis (TB) and  
 858 radiographic disease severity. Coloured boxes highlight statistically significant correlations ( $p < 0.05$ ).  
 859 **(B, C)** Network diagrams of statistically significant ( $FDR < 0.05$ ) cytokines **(B)** and transcription factors  
 860 **(C)** predicted to be upstream regulators (red) of target gene modules (blue) whose expression is  
 861 negatively correlated with radiological TB severity. Size of the nodes for upstream regulators is  
 862 proportional to  $-\log_{10} p$  value. Nodes were clustered using the Force Atlas 2 algorithm in Gephi  
 863 (version 0.9.2). **(D, E)** The inverse relationship between average expression in each TST sample of  
 864 two distinct, independently derived gene modules representing type I interferon activity **(D)** with TB  
 865 severity **(E)**.  $r$  values and  $p$  values were derived from two-tailed Spearman rank correlations. CXR =  
 866 Chest x-ray,  $M\Phi$  = Macrophage, KC = Keratinocyte.

867

868



869



870

871 **Fig. 2. *M. marinum* infection induces a type I interferon response in zebrafish larvae.**

872 **(A)** Schematic representation of the human canonical type I interferon signalling pathway (left) which

873 is highly conserved in zebrafish (right). **(B, C)** The average expression of two largely non-overlapping

874 **(B)** type I interferon inducible gene modules derived from independent data (Table S1) is elevated


875 in *M. marinum* (Mm) infected embryos (4 days post-intravenous infection) compared with uninfected

876 (UI) siblings **(C)**. Data are from four independent experiments.

877

878

879



880

881

882

883

884

885

886

887

888

889


890

891

892

**Fig. 3. Increased severity of *M. marinum* infection in *stat2* CRISPs.** (A) *stat2* CRISPs (*stat2*<sup>-/-</sup>) and control ribonucleoprotein (RNP) injected (*stat2*<sup>+/+</sup>) zebrafish larvae four days post intravenous infection with 400 colony forming units (cfu) mCherry-expressing *M. marinum*. Scale bar = 250  $\mu$ m. (B) Survival of control and *stat2* disrupted zebrafish larvae 1-4 days post infection with *M. marinum*. p value was derived from a log-rank (Mantel-Cox) test. (C-E) Comparison of integrated fluorescence (IF) (a surrogate for bacterial burden) (C), number of bacterial foci (D) and spatial distribution of bacteria (E), in *stat2* CRISPs compared to control RNP injected siblings. Each data point represents an individual zebrafish larva, lines and error bars indicate the median and interquartile range. p values were derived from two-tailed Mann-Whitney tests. Data are representative of four experiments.

893



894


895 **Fig. 4. Reduced steady state neutrophil numbers in *stat2* CRISPAnts.** (A) Representative  
896 images of three day post-fertilisation (dpf) control (upper panel) and *stat2* CRISPAnt (lower panel)  
897 *Tg(mpeg1:mCherry)* zebrafish larvae. Scale bar = 250  $\mu$ m. (B) Integrated fluorescence (IF) as a  
898 surrogate for steady state macrophage numbers in three dpf *stat2* CRISPAnts compared to siblings  
899 injected with scrambled RNPs. (C) Representative images of two dpf control (upper panel) and *stat2*  
900 CRISPAnt (lower panel) *Tg(mpx:eGFP)* zebrafish larvae. Scale bar = 250  $\mu$ m. (D) Quantitation of  
901 baseline neutrophil numbers (represented by IF) in two dpf *stat2* CRISPAnts and negative control  
902 RNP injected siblings. Each data point represents an individual zebrafish larva, lines and error bars  
903 indicate the median and interquartile range. p values were derived from two-tailed Mann-Whitney  
904 tests. Data are from three independent experiments.

905

906

Protective type I interferon responses in mycobacterial infection

907



908


909 **Fig. 5. Neutrophil recruitment to the site of sterile injury is not *stat2* dependent.**  
 910 **(A)** Representative images of eGFP-expressing neutrophils recruited to the site of injury 1, 6 and 24  
 911 hours following tailfin transection of three day post-fertilisation *stat2* CRISPRant *Tg(mpx:eGFP)*  
 912 zebrafish larvae and scrambled RNP injected controls. Scale bar represents 100  $\mu$ m. **(B)** Distance of neutrophils from the injury site at 1, 6 and 24 hours post-wound (hpw), derived by identifying the  
 913 Sholl circle in which the maximum integrated fluorescence (IF), a surrogate for highest cell numbers,  
 914 was detected in *stat2* CRISPRants and scrambled RNP injected siblings. **(C-D)** IF, a surrogate for  
 915 total neutrophil numbers **(C)**, and IF at the wound site, representing neutrophil numbers localized to  
 916 the tailfin transection **(D)** are shown at 1, 6 and 24 hours following injury. On scatter plots data points  
 917 represent individual zebrafish larvae and lines and error bars the median and interquartile range. On  
 918 box and whisker plots horizontal lines represent median values, box limits indicate the interquartile  
 919 range and whiskers extend between the 5th and 95th percentiles. p values were derived from two-  
 920 tailed Mann-Whitney tests. \* = p < 0.05. Data are from three independent experiments. px = Pixels.

922

923



924



925

926

927

928

929

930

931

932

933

934

935


936

937

938

**Fig. 6. Reduced macrophage recruitment to the site of sterile injury in *stat2* CRISPRants.** **(A)** Representative images of mCherry-expressing macrophages recruited to the site of tailfin transection by 6 and 24 hours, in three day post-fertilisation *stat2* CRISPRant *Tg(mpeg1:mCherry)* zebrafish embryos and controls. Scale bar represents 100  $\mu$ m. **(B)** Comparison of the distance of macrophages from the site of injury at the indicated time points for *stat2* CRISPRants and control RNP injected siblings. **(C)** Integrated fluorescence (IF) a surrogate for macrophage numbers at the site of tailfin transection is shown at 1, 6 and 24 hours post-wound (hpw). On scatter plots data points represent individual zebrafish larvae and lines and error bars the median and interquartile range. On box and whisker plots horizontal lines represent median values, box limits indicate the interquartile range and whiskers extend between the 5th and 95th percentiles. p values were derived from two-tailed Mann-Whitney tests. \* = p<0.05. Data are from three independent experiments. px = Pixels.

939



940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

**Fig. 7. Reduced macrophage and neutrophil recruitment to *M. marinum* in *stat2* CRISPs.** (A) Representative images of mCherry-expressing macrophages recruited to the hindbrain (dashed white outline) 18 hours following injection of PBS or 200 colony forming units (cfu) *M. marinum* in two day post-fertilisation (dpf) *stat2* CRISPs and control *Tg(mpeg1:mCherry)* zebrafish larvae and scrambled ribonucleoprotein (RNP) injected controls. (B) Number of macrophages recruited to the hindbrain in response to PBS or *M. marinum* in *stat2* CRISPs and negative control RNP injected siblings. (C) Representative images of eGFP-expressing neutrophils recruited to the hindbrain 6 hours after PBS or *M. marinum* injection (200 cfu) in two dpf *stat2* CRISPs and control *Tg(mpx:eGFP)* zebrafish larvae. (D) Quantitation of neutrophils recruited to the site of *M. marinum* infection in *stat2* CRISPs and control siblings. Scale bars represent 100  $\mu$ m. Data points represent individual zebrafish larvae and lines and error bars the median and interquartile range. p values were derived from two-tailed Mann-Whitney tests. \* = p < 0.05. Data are from three independent experiments.

955 **TABLES**

956 **Table 1. Clinical and demographic data summary.** Demographic characteristics and magnitude  
 957 of clinical induration at the site of TST or saline injection are summarised for all study subjects.  
 958 Duration of anti-tuberculous drug treatment at the time of sampling and radiographic disease severity  
 959 data are provided for individuals with pulmonary TB. Saline samples were obtained from 17  
 960 individuals with pulmonary TB and 32 healthy participants who were people with cured or latent TB,  
 961 BCG vaccine recipients and healthy volunteers, described previously (8). CXR = chest x-ray.  
 962 \*Applies only to participants with active TB receiving saline injections.

		TST	Saline
Number		51	49
Age	(median and range)	30 (19-77)	28 (18-75)
Sex	Male	31 (61%)	19 (39%)
	Female	20 (39%)	30 (61%)
Ethnicity	White	21 (41%)	20 (41%)
	Asian	15 (29%)	8 (16%)
	Black	12 (24%)	7 (14%)
	Mixed	2 (4%)	1 (2%)
	South American	1 (2%)	11 (22%)
	Not recorded	NA	2 (4%)
	Injection site induration (mm)	(median and range)	20 (0-70)
Days TB treatment before TST +/- saline	(median and range)	19 (0-30)	15 (0-28)*
CXR severity score	(median and range)	30 (0-140)	15 (0-110)*

963